EdgarLookup

SELECT MEDICAL HOLDINGS CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that SELECT MEDICAL HOLDINGS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
2.7%
Profit Margin
Net income ÷ revenue
2.5%
Return on Assets
Net income ÷ assets
2.24x
Debt-to-Equity
Total liabilities ÷ equity
+315.4%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.45B Feb 19, 2026
FY2024 Dec 31, 2024 $1.31B Feb 20, 2025
FY2024 Sep 30, 2024 $1.27B Feb 20, 2025
FY2024 Jun 30, 2024 $1.28B Feb 20, 2025
FY2024 Mar 31, 2024 $1.32B Feb 20, 2025
FY2024 Dec 31, 2023 $1.22B Feb 20, 2025
FY2024 Sep 30, 2023 $1.19B Feb 20, 2025
FY2024 Jun 30, 2023 $1.21B Feb 20, 2025
FY2024 Mar 31, 2023 $1.21B Feb 20, 2025
FY2024 Dec 31, 2022 $4.61B Feb 20, 2025

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $146.22M Feb 19, 2026
FY2024 Dec 31, 2024 ($16.05M) Feb 20, 2025
FY2024 Sep 30, 2024 $55.63M Feb 20, 2025
FY2024 Jun 30, 2024 $77.56M Feb 20, 2025
FY2024 Mar 31, 2024 $96.90M Feb 20, 2025
FY2024 Dec 31, 2023 $46.27M Feb 20, 2025
FY2024 Sep 30, 2023 $48.18M Feb 20, 2025
FY2024 Jun 30, 2023 $78.24M Feb 20, 2025
FY2024 Mar 31, 2023 $70.81M Feb 20, 2025
FY2024 Dec 31, 2022 $158.99M Feb 20, 2025

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $336.17M Feb 19, 2026
FY2025 Dec 31, 2024 $268.32M Feb 19, 2026
FY2025 Dec 31, 2023 $267.24M Feb 19, 2026
FY2024 Dec 31, 2022 $144.75M Feb 20, 2025
FY2023 Dec 31, 2021 $713.77M Feb 22, 2024
FY2020 Dec 31, 2020 $163.33M Feb 25, 2021
FY2020 Sep 30, 2020 $156.13M Feb 25, 2021
FY2020 Jun 30, 2020 $119.52M Feb 25, 2021
FY2020 Mar 31, 2020 $128.68M Feb 25, 2021
FY2020 Dec 31, 2019 $112.37M Feb 25, 2021

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $346.47M Feb 19, 2026
FY2025 Dec 31, 2024 $517.86M Feb 19, 2026
FY2025 Dec 31, 2023 $582.06M Feb 19, 2026
FY2024 Dec 31, 2022 $284.83M Feb 20, 2025
FY2023 Dec 31, 2021 $401.23M Feb 22, 2024
FY2022 Dec 31, 2020 $1.03B Feb 23, 2023
FY2021 Dec 31, 2019 $445.18M Feb 24, 2022
FY2020 Dec 31, 2018 $494.19M Feb 25, 2021
FY2019 Dec 31, 2017 $238.13M Feb 20, 2020
FY2018 Dec 31, 2016 $346.60M Feb 21, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.85B Feb 19, 2026
FY2025 Dec 31, 2024 $5.61B Feb 19, 2026
FY2024 Dec 31, 2023 $7.69B Feb 20, 2025
FY2023 Dec 31, 2022 $7.67B Feb 22, 2024
FY2023 Dec 31, 2021 $7.36B Feb 22, 2024
FY2022 Dec 31, 2020 $7.66B Feb 23, 2023
FY2021 Dec 31, 2019 $7.34B Feb 24, 2022
FY2020 Dec 31, 2018 $5.96B Feb 25, 2021
FY2019 Dec 31, 2017 $5.13B Feb 20, 2020
FY2018 Dec 31, 2016 $4.92B Feb 21, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.82B Feb 19, 2026
FY2025 Dec 31, 2024 $3.61B Feb 19, 2026
FY2024 Dec 31, 2023 $6.12B Feb 20, 2025
FY2023 Dec 31, 2022 $6.27B Feb 22, 2024
FY2022 Dec 31, 2021 $6.00B Feb 23, 2023
FY2021 Dec 31, 2020 $6.00B Feb 24, 2022
FY2020 Dec 31, 2019 $5.44B Feb 25, 2021
FY2019 Dec 31, 2018 $4.27B Feb 20, 2020
FY2018 Dec 31, 2017 $3.55B Feb 21, 2019
FY2017 Dec 31, 2016 $3.59B Feb 22, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.71B Feb 19, 2026
FY2025 Dec 31, 2024 $1.68B Feb 19, 2026
FY2024 Dec 31, 2023 $1.29B Feb 20, 2025
FY2023 Dec 31, 2022 $1.12B Feb 22, 2024
FY2022 Dec 31, 2021 $1.11B Feb 23, 2023
FY2021 Dec 31, 2020 $1.06B Feb 24, 2022
FY2020 Dec 31, 2019 $770.97M Feb 25, 2021
FY2019 Dec 31, 2018 $803.04M Feb 20, 2020
FY2018 Dec 31, 2017 $823.37M Feb 21, 2019
FY2017 Dec 31, 2016 $815.73M Feb 22, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.36B Feb 19, 2026
FY2025 Dec 31, 2024 $2.33B Feb 19, 2026
FY2025 Dec 31, 2023 $2.28B Feb 19, 2026
FY2024 Dec 31, 2022 $2.26B Feb 20, 2025
FY2023 Dec 31, 2021 $3.45B Feb 22, 2024
FY2022 Dec 31, 2020 $3.38B Feb 23, 2023
FY2021 Dec 31, 2019 $3.39B Feb 24, 2022
FY2020 Dec 31, 2018 $3.32B Feb 25, 2021
FY2019 Dec 31, 2017 $2.78B Feb 20, 2020
FY2018 Dec 31, 2016 $2.75B Feb 21, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $837.02M Feb 19, 2026
FY2025 Dec 31, 2024 $770.15M Feb 19, 2026
FY2024 Dec 31, 2023 $751.86M Feb 20, 2025
FY2023 Dec 31, 2022 $581.01M Feb 22, 2024
FY2022 Dec 31, 2021 $593.25M Feb 23, 2023
FY2021 Dec 31, 2020 $553.24M Feb 24, 2022
FY2020 Dec 31, 2019 $279.80M Feb 25, 2021
FY2019 Dec 31, 2018 $320.35M Feb 20, 2020
FY2018 Dec 31, 2017 $359.74M Feb 21, 2019
FY2017 Dec 31, 2016 $371.69M Feb 22, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $26.52M Feb 19, 2026
FY2025 Dec 31, 2024 $59.69M Feb 19, 2026
FY2024 Dec 31, 2023 $52.63M Feb 20, 2025
FY2023 Dec 31, 2022 $97.91M Feb 22, 2024
FY2022 Dec 31, 2021 $74.31M Feb 23, 2023
FY2021 Dec 31, 2020 $577.06M Feb 24, 2022
FY2020 Dec 31, 2019 $335.88M Feb 25, 2021
FY2019 Dec 31, 2018 $175.18M Feb 20, 2020
FY2018 Dec 31, 2017 $122.55M Feb 21, 2019
FY2018 Dec 31, 2016 $99.03M Feb 21, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2019 $3.45B Feb 20, 2020
FY2019 Dec 31, 2018 $3.29B Feb 20, 2020
FY2018 Dec 31, 2017 $2.70B Feb 21, 2019
FY2017 Dec 31, 2016 $2.70B Feb 22, 2018
FY2014 Dec 31, 2014 $1.55B Feb 25, 2015
FY2014 Dec 31, 2013 $1.45B Feb 25, 2015
FY2013 Dec 31, 2012 $1.47B Feb 25, 2014
FY2012 Dec 31, 2011 $1.40B Feb 26, 2013

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 1 Feb 19, 2026
FY2025 Dec 31, 2024 1 Feb 19, 2026
FY2025 Dec 31, 2023 1 Feb 19, 2026
FY2024 Dec 31, 2022 1 Feb 20, 2025
FY2023 Dec 31, 2021 2 Feb 22, 2024
FY2020 Dec 31, 2020 0 Feb 25, 2021
FY2020 Sep 30, 2020 0 Feb 25, 2021
FY2020 Jun 30, 2020 0 Feb 25, 2021
FY2020 Mar 31, 2020 0 Feb 25, 2021
FY2020 Dec 31, 2019 0 Feb 25, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 1 Feb 19, 2026
FY2025 Dec 31, 2024 1 Feb 19, 2026
FY2025 Dec 31, 2023 1 Feb 19, 2026
FY2024 Dec 31, 2022 1 Feb 20, 2025
FY2023 Dec 31, 2021 2 Feb 22, 2024
FY2020 Dec 31, 2020 0 Feb 25, 2021
FY2020 Sep 30, 2020 0 Feb 25, 2021
FY2020 Jun 30, 2020 0 Feb 25, 2021
FY2020 Mar 31, 2020 0 Feb 25, 2021
FY2020 Dec 31, 2019 0 Feb 25, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 124.02M Feb 19, 2026
FY2025 Dec 31, 2024 128.96M Feb 19, 2026
FY2024 Dec 31, 2023 128.37M Feb 20, 2025
FY2023 Dec 31, 2022 127.17M Feb 22, 2024
FY2022 Dec 31, 2021 133.88M Feb 23, 2023
FY2021 Dec 31, 2020 134.85M Feb 24, 2022
FY2020 Dec 31, 2019 134.33M Feb 25, 2021
FY2019 Dec 31, 2018 135.27M Feb 20, 2020
FY2018 Dec 31, 2017 134.11M Feb 21, 2019
FY2017 Dec 31, 2016 132.60M Feb 22, 2018

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $31.44M Feb 19, 2026
FY2025 Dec 31, 2024 $64.62M Feb 19, 2026
FY2025 Dec 31, 2023 $63.90M Feb 19, 2026
FY2024 Dec 31, 2022 $64.59M Feb 20, 2025
FY2023 Dec 31, 2021 $50.60M Feb 22, 2024
FY2022 Dec 31, 2020 $0 Feb 23, 2023
FY2021 Dec 31, 2019 $0 Feb 24, 2022
FY2017 Dec 31, 2017 $0 Feb 22, 2018
FY2017 Dec 31, 2016 $0 Feb 22, 2018
FY2017 Dec 31, 2015 $13.13M Feb 22, 2018